


(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/25219 A2(51) International Patent Classification⁷: **C07D 241/04,**
A61K 31/496, A61P 25/22[IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming 2,
I-37135 Verona (IT).(21) International Application Number: **PCT/EP00/09722**(74) Agent: **FILLER, Wendy, Anne;** Glaxo Wellcome plc,
Glaxo Wellcome House, Berkeley Avenue, Greenford,
Middlesex UB6 0NN (GB).(22) International Filing Date: **5 October 2000 (05.10.2000)**(25) Filing Language: **English**(26) Publication Language: **English**(30) Priority Data:
9923748.9 7 October 1999 (07.10.1999) **GB**(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(71) Applicant (*for all designated States except US*): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ALVARO, Giuseppe**
[IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming 2,
I-37135 Verona (IT). **DI FABIO, Romano** [IT/IT]; Glaxo
Wellcome SpA, Via Alessandro Fleming 2, I-37135 Verona
(IT). **GIOVANNINI, Riccardo** [IT/IT]; Glaxo Wellcome
SpA, Via Alessandro Fleming 2, I-37135 Verona (IT).
GUERCIO, Giuseppe [IT/IT]; Glaxo Wellcome SpA, Via
Alessandro Fleming 2, I-37135 Verona (IT). **ST-DENIS,**
Yves [CA/IT]; Glaxo Wellcome SpA, Via Alessandro
Fleming 2, I-37135 Verona (IT). **URSINI, Antonella****Published:**— *Without international search report and to be republished
upon receipt of that report.**For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*(54) Title: **CHEMICAL COMPOUNDS**

(57) Abstract: The present invention relates to piperazine derivatives of formula (I) wherein R represents a halogen atom or a C₁₋₄ alkyl group; R₁ represents hydrogen or a C₁₋₄ alkyl group; R₂ represents hydrogen, a C₁₋₄ alkyl, C₂₋₆ alkenyl or a C₃₋₇ cycloalkyl group; or R₁ and R₂ together with nitrogen and carbon atom to which they are attached respectively represent a 5-6 membered heterocyclic group; R₃ represents a trifluoromethyl, a C₁₋₄ alkyl, a C₁₋₄ alkoxy, a trifluoromethoxy or a halogen group; R₄ represents hydrogen, a (CH₂)_qR₇ or a (CH₂)_rCO(CH₂)_pR₇ group; R₅ represents hydrogen, a C₁₋₄ alkyl or a COR₆ group; R₆ represents hydrogen, hydroxy, amino, methylamino, dimethylamino a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen or a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms; R₇ represents hydrogen,

hydroxy or NR₈R₉, wherein R₈ and R₉ represent independently hydrogen or C₁₋₄ alkyl optionally substituted by hydroxy, or by amino; R₁₀ represents hydrogen, a C₁₋₄ alkyl I group or R₁₀ together with R₂ represents a C₃₋₇ cycloalkyl group; m is zero or an integer from 1 to 3; n is zero or an integer from 1 to 3; both p and r are independently zero or an integer from 1 to 4; q is an integer from 1 to 4; provided that, when R₁ and R₂ together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group, i) m is 1 or 2; ii) when m is 1, R is not fluorine and iii) when m is 2, the two substituents R are not both fluorine, and pharmaceutically acceptable salts and solvates thereof.